SAB4301029
Anti-SLC34A2 antibody produced in rabbit
affinity isolated antibody
Synonym(s):
NAPI-3B, NAPI-IIb, NPTIIb
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human
concentration
2.4 mg/mL
technique(s)
immunohistochemistry: 1:100- 1:300
isotype
IgG
accession no.
NP_001171469.1
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... SLC34A2(10568)
General description
Solute carrier family 34 member 2 (SLC34A2) is a transmembrane protein, which belongs to SLC34 family. The protein encoded by SLC34A2 is a sodium-dependent phosphate transporter type IIb (NaPi-IIb). It is a pH-sensitive transporter, expressed in small intestine, liver and lung. NaPi-IIb expression is also observed in female genital tract, endometrium, cervix, fallopian tube and not in ovary. In human chromosome, the gene SLC34A2 is localized on 4p15.2.
Specificity
The antibody detects endogenous levels of total SLC34A2 protein.
Immunogen
Synthetic peptide corresponding to residues near the C terminal of human Solute carrier family 34 (sodium phosphate), member 2
Biochem/physiol Actions
Solute carrier family 34 member 2 (SLC34A2) cotransports inorganic phosphate ion and sodium ion into epithelial cells. SLC34A2 is associated with various malignancies like papillary thyroid and breast carcinoma and lung adenocarcinoma. Knockdown of SLC34A2 downregulates phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signalling pathway, in turn inhibiting tumour cell proliferation and metastasis of hepatocellular carcinoma. SLC34A2 promotes tumour proliferation of bladder cancer, through upregulation of proto-oncogene c-Myc. Fetal and early embryonic development of lung requires high expression of SLC33A2 and is downregulated in NSCLC (non-small cell lung carcinoma). High expression of NaPi-IIb is observed in epithelial ovarian cancer. Overexpression of SLC34A2 promotes colorectal cancer progression. Mutations in SLC34A2 is related to pulmonary alveolar microlithiasis.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in pH7.3 PBS, 0.05% NaN3, 50% Glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer
Liu L, et al.
Biomedicine and Pharmacotherapy, 99, 645-654 (2018)
A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis
Izumi H, et al.
Human Genome Variation, 4, 16047-16047 (2017)
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
Levan K, et al.
BMC Cancer, 17(1), 303-303 (2017)
Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity
Ye W, et al.
Cell Death & Disease, 8(2), e2581-e2581 (2017)
MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/beta-catenin pathway
Zhang X, et al.
Oncotarget, 7(12), 14569-14585 (2016)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service